Furthermore, the IL-6 knockdown mitigates CRS by reducing pro-inflammatory cytokines such as IL-2, TNF-α, and IFN-γ after T cell reprogramming, thus improving the safety of CAR-T treatments [62]. This evidence concerns the gene IL2 and congenital rubella syndrome.